After ten years of clinical evidence, Knee Joint Distraction proves joint preservation is possible, delaying knee replacement, restoring function, and redefining osteoarthritis treatment for younger, active patients.

A 22-year-old patient returned to active life seven months after KneeReviver treatment. This case highlights the impact of Knee Joint Distraction.

Discover how ArthroSave’s co-founder and CEO from 2016-2025 Karianne Lindenhovius turned groundbreaking research into a decade of growth, innovation, and patient impact through Knee Joint Distraction, preserving natural knees and restoring active lives.

KJD shows promise for young knee OA patients—delaying TKA, improving pain and function, and enabling tissue repair. This mini-review highlights 2021–2024 advances and remaining research gaps.

A groundbreaking therapy from the Netherlands offers regeneration instead of replacement: Knee Joint Distraction (KJD) could halt – or even reverse – osteoarthritis. Early results offer hope to many.

Orthopedic surgeon Peter van Roermund wins the SAMMIE Award for pioneering knee distraction therapy—an innovative, joint-preserving treatment offering new hope for younger patients with severe knee osteoarthritis.

A groundbreaking study reveals KJD-regenerated cartilage closely matches native tissue, offering the first molecular proof of regeneration—marking a major step forward in joint-preserving osteoarthritis treatment.

Explore the latest in cartilage treatments! The SIAGASCOT Committee unveils a special “Papers in Pills” issue spotlighting key insights from ICRS 2024 — including breakthroughs in knee joint distraction.

Discover how NDR’s “Visite” spotlighted innovative osteoarthritis treatments, including ArthroSave’s KneeReviver, with expert insights on distraction therapy from leading German clinicians and orthopedic specialists.

El Correo explores Knee Joint Distraction as a breakthrough for cartilage regeneration—offering new hope to osteoarthritis patients through joint-preserving innovation and promising clinical outcomes.

Suffering from knee osteoarthritis and under 66? Discover the innovative GODiVA trial in the Netherlands—exploring knee distraction as an alternative to replacement. Join the study and shape future treatment.

Der Spiegel highlights KneeReviver’s breakthrough: knee joint distraction shows potential to reverse osteoarthritis and relieve pain—delaying prosthesis surgery and offering a future free of knee pain.

New research using AI reveals that patients undergoing knee joint distraction (KJD) show improved joint space and reduced pain, linking radiographic changes to synovial biomarkers and clinical outcomes.

ArthroSave’s innovative KneeReviver device enables knee joint distraction, offering pain relief, functional improvement, and delaying knee replacement surgery by up to 10 years for osteoarthritis patients across Europe.

A €10 million NWO-funded consortium led by Erasmus MC will explore personalized joint loading strategies to help osteoarthritis patients exercise safely and reduce joint damage progression.

A UMC Utrecht study confirms lasting cartilage regeneration 10 years after knee distraction, offering strong evidence for the long-term joint-preserving potential of this innovative osteoarthritis treatment.

Michelle Teunissen’s PhD research bridges human and veterinary medicine, revealing how knee distraction promotes cartilage and bone growth—even saving a dog with severe osteoarthritis from euthanasia.